ema glp-1 vision loss recommendation november 2025 Indiana woman reports after taking drug; scientific research suggests drugs potentially increase risk for 'eye stroke' GLP-1 drugs may be linked

Clinician fit, supply, and goal-matching still stay part of the decision

IV and short-duration oral trials METAOD001-004 enrolled smaller groups of healthy or obese men with single doses or 1-week dosing across IV (25-400 mcg/kg) and oral (9-54 mg) routes

Most episodes of gastrointestinal events were mild or moderate and did not lead to discontinuation of therapy (6.2% with SAXENDA versus 0.8% with placebo discontinued treatment as a result of gastrointestinal adverse reactions)

Tirzepatide also resulted in dose-dependent reductions in body weight, with significant weight loss compared to dulaglutide

First, we tested the levels of neurotoxic aggregating proteins